Sartorius products at work against COVID-19
Many of our customers are working hard to find a vaccine against the coronavirus. Here are some examples of how Sartorius technologies simplify progress in their important work.
This article is posted on our Sartorius Blog.
Biostat Bioreactors reduce time and costs required to bring vaccines to the clinic
Our customer CanSino Biologics and Beijing Institute of Biotechnology recently got approval for their vaccine candidate for COVID-19 to enter a Phase 1 clinical trial -- the first candidate to reach this stage in China. The customer is using Sartoriusʼ Biostat STR 200L bioreactors to prepare clinical samples.
Virus counter platform enables more rapid development of COVID19 vaccines
The Sartorius Virus Counter platform reduces experimentation and testing timelines in the development of a vaccine against COVID-19 by delivering precise results in near real-time.
Cellulose nitrate membranes accelerate screening
In China, Sartorius supplies cellulose nitrate membranes to roughly 70 biopharmaceutical companies who develop new quick test kits as an important supplement to the standard diagnostics. These test kits deliver results within just 15 to 20 minutes.
Sartobind membranes enable efficient purification of viruses in vaccine production
To gain antigens for a vaccine, viruses are cultivated in bioreactors. Sartobind membrane chromatography helps vaccine manufacturers separate coronavirus antigens from the cells or proteins in which they have grown.
